LONDON and PHILADELPHIA – May 29, 2026 – Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, today announces that its Annual Report and Accounts for the year ended December 31, 2025 and the Notice of Annual General Meeting (AGM) are available on the Company’s website.
Copies of the Annual Report and Accounts and the Notice of AGM will be posted today to registered shareholders who have elected to receive them in paper form.
The AGM will be held on Monday, June 22, 2026 at 9:00 BST. The meeting will be held at Glaziers Hall, 9 Montague Close, London Bridge, SE1 9DD (the “Venue”).
Registered shareholders have a right to attend the AGM. In addition, the current expectation is that the chair of the AGM will, at their discretion, permit beneficial shareholders to attend in person. Shareholders (registered or beneficial) who propose to attend the AGM in person are requested to pre-register their interest and, to assist the Company in its preparation for the AGM, prove their shareholding by emailing their letter of representation to investors@avacta.com by 8.00 p.m. on 20 June 2026. Any failure to pre-register will not, of itself, preclude a registered shareholder from attending the AGM in person (or by proxy).
Only registered shareholders who attend in person or by proxy will be able to vote on the day. Details of how to submit a proxy vote are contained in the Notice of the AGM.
The Company will provide a business update following the AGM, which will be recorded and uploaded on the Company’s website for shareholders who are not able to attend in person. All presentation materials will be made available on the website at the end of the day and no new material information will be provided.